This novel DNA device improves photodynamic therapy and miRNA-210 imaging in hypoxic lung cancer, suggesting new treatment approaches.
In this work, we construct a glutathione (GSH)-activated DNA nanodevice conjugated to a porphyrin-based metal–organic framework (PCN-224), creating an integrated theranostic platform for modulating hypoxia, enabling miRNA-210-specific imaging and enhancing...
No takes yet. Share an insight, caveat, or question.
Meng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: